Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More